PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Pain: Overview PART 05: Pipeline portfolio • Information on pipeline candidates PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by drug class • Opioids • NSAIDs • Other • Global opioids market • Global NSAIDs Market PART 08: Market segmentation by type • Prescription analgesics • OTC analgesics PART 09: Market segmentation by application • Global internal analgesics market • Global external analgesics market PART 10: Market segmentation by pain type • Musculoskeletal pain • Surgical and trauma pain • Cancer pain • Neuropathic pain • Migraine • Obstetrical pain Fibromyalgia • Pain due to burns • Dental/facial pain • Pediatric pain PART 11: Market segmentation by ROA • Oral • Parenteral • Topical • Transdermal • Rectal PART 12: Geographical segmentation • Analgesics market in Americas • Analgesics market in EMEA • Analgesics market in APAC PART 13: Market drivers • Growing geriatric population • Increase in self-medication • Promising pipeline • Favorable regulatory scenario PART 14: Impact of drivers PART 15: Market challenges • Generic competition • Preference for alternative therapies • Counterfeit pharmaceuticals PART 16: Impact of drivers and challenges PART 17: Market trends • Accelerated use of online resources • Increase in R&D • Off-label drugs use • Strategic alliances PART 18: Vendor landscape • Competitive scenario • Market share analysis 2015 • Pfizer • Bayer Healthcare • Sanofi • Endo International • Johnson & Johnson • Purdue Pharma • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Pain assessment Exhibit 03: Types of pain scales Exhibit 04: Treatment options for pain Exhibit 05: Commonly used non-opioids for pain Exhibit 06: Commonly used adjuvant medicines for pain Exhibit 07: Treatment algorithm for pain Exhibit 08: Pipeline portfolio: Major analgesic candidates under development for pain Exhibit 09: Global analgesics market 2015-2020 ($ billions) Exhibit 10: Five forces analysis Exhibit 11: Global analgesics market by drug class Exhibit 12: Segmentation of global analgesics market by drug class 2015 Exhibit 13: Global analgesics market segmentation by drug class 2015-2020 ($ billions) Exhibit 14: Global analgesics market segmentation by drug class 2015-2020 Exhibit 15: Global analgesics market: YoY revenue and growth based on drug class 2015-2020 ($ billions) Exhibit 16: Global opioids market 2015-2020 ($ billions) Exhibit 17: Global NSAIDs market 2015-2020 ($ billions) Exhibit 18: Global analgesics segmentation by type Exhibit 19: Global analgesics segmentation by type 2015 Exhibit 20: Global analgesics market segmentation by type 2015-2020 ($ billions) Exhibit 21: Global analgesics market segmentation by type 2015-2020 Exhibit 22: Global analgesics market: YoY revenue and growth based on type 2015-2020 ($ billions) Exhibit 23: Global prescription analgesics market 2015-2020 ($ billions) Exhibit 24: Global OTC analgesics market 2015-2020 ($ billions) Exhibit 25: Global analgesics market segmentation by application Exhibit 26: Global internal analgesics market 2015-2020 ($ billions) Exhibit 27: Global external analgesics market 2015-2020 ($ billions) Exhibit 28: Global analgesics market segmentation by application 2015-2020 ($ billions) Exhibit 29: Global analgesics market segmentation by application 2015-2020 Exhibit 30: Global analgesics market: YoY revenue and growth based on application 2015-2020 ($ billions) Exhibit 31: Global analgesics market segmentation by type Exhibit 32: Global analgesics market segmentation by type 2015 Exhibit 33: Global analgesics market segmentation by ROA Exhibit 34: Global analgesics market segmentation by ROA 2015 Exhibit 35: Global analgesics market by geography 2015 Exhibit 36: Global analgesics market revenue by geography 2015-2020 ($ billions) Exhibit 37: Global analgesics market revenue by geography 2015-2020 Exhibit 38: Global analgesics market: YoY revenue and growth based on geography 2015-2020 ($ billions) Exhibit 39: Analgesics market in Americas 2015-2020 ($ billions) Exhibit 40: Analgesics market in EMEA 2015-2020 ($ billions) Exhibit 41: Analgesics market in APAC 2015-2020 ($ billions) Exhibit 42: Population aged 60 years and over: World, developed, and developing regions (millions) Exhibit 43: Expected growth of older population in US 2010-2050 Exhibit 44: Impact of drivers Exhibit 45: Alternative therapies for pain Exhibit 46: Use of CAM therapies among individuals in US Exhibit 47: Impact of drivers and challenges Exhibit 48: Global Internet penetration rate 2015 Exhibit 49: Market share analysis 2015 Exhibit 50: Revenue share of major companies for global analgesics market 2015 Exhibit 51: Revenues from the sales of top five analgesics 2013-2015 ($ millions) Exhibit 52: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 53: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions) Exhibit 54: Pfizer: YoY revenue and growth rate of Relpax 2013-2015 ($ millions) Exhibit 55: Pfizer: Key takeaways Exhibit 56: Bayer HealthCare: YoY revenue and growth rate of Aspirin 2013-2015 ($ millions) Exhibit 57: Bayer HealthCare: YoY revenue and growth rate of Aleve 2013-2015 ($ millions) Exhibit 58: Bayer HealthCare: Key takeaways Exhibit 59: Sanofi: YoY revenue and growth rate of Doliprane 2013-2015 ($ millions) Exhibit 60: Sanofi: YoY revenue and growth rate of Dorflex 2013-2015 ($ millions) Exhibit 61: Sanofi: YoY revenue and growth rate of Synvisc/Synvisc One 2013-2015 ($ millions) Exhibit 62: Sanofi: YoY revenue and growth rate of No Spa 2013-2015 ($ millions) Exhibit 63: Sanofi: Key takeaways Exhibit 64: Endo International: YoY revenue and growth rate of Opana ER 2013-2015 ($ millions) Exhibit 65: Endo International: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions) Exhibit 66: Endo International: YoY revenue and growth rate of Lidoderm 2013-2015 ($ millions) Exhibit 67: Endo International: YoY revenue and growth rate of Percocet 2013-2015 ($ millions) Exhibit 68: Endo International: Key takeaways Exhibit 69: Johnson & Johnson: Key takeaways Exhibit 70: Purdue Pharma: Key takeaways

Pfizer, Bayer HealthCare, Sanofi, Endo International, Johnson & Johnson, Purdue Pharma, Achelios Therapeutics, Alder BioPharmaceuticals, Allergan, Amgen, AstraZeneca, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, CoLucid Pharmaceuticals, Daiichi Sankyo, Dr. Reddy's Laboratories, DURECT, El Lilly & Company, F. Hoffmann La Roche, GlaxoSmithKline, GW Pharmaceuticals, Hospira, Immune Pharmaceuticals, Innovative Med Concepts, Merck, NeurAxon, Novartis, OptiNose, Pain Therapeutics, RedHill, Sorrento Therapeutics, Suda, Taro Pharmaceuticals Industries, Teva Pharmaceuticals Industries, Tonix Pharmaceuticals, Trigemina, UCB, Valeant Pharmaceuticals International, WEX Pharmaceuticals, Zynerba Pharmaceuticals.